IMMUTEP Ltd (IMMP) stock
IMMPNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as PRRUF
$3.26−0.14 (-4.12%)
Close on Nov 17, 2026Market cap $24.02MP/E –Yield –
Immutep price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Immutep's price to sales ratio was 1.6× on Nov 11, 2026, against 43.7× a year earlier. Over the last 5 years it ranged from 1.3× to 77.0×, with a median of 44.1×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.6× | −58.9 |
| 2025 | Dec 31, 2025 | 60.4× | +6.7 |
| 2024 | Dec 31, 2024 | 53.8× | −6.6 |
| 2023 | Dec 29, 2023 | 60.3× | +28.0 |
| 2022 | Dec 30, 2022 | 32.3× | −35.4 |
| 2021 | Dec 31, 2021 | 67.7× | +57.5 |
| 2020 | Dec 31, 2020 | 10.2× | −1.6 |
| 2019 | Dec 31, 2019 | 11.8× | +2.0 |
| 2018 | Dec 31, 2018 | 9.8× | −2.1 |
| 2017 | Dec 29, 2017 | 11.9× | −25.5 |
| 2016 | Dec 30, 2016 | 37.4× | – |
See a number that looks wrong?